Corvus Pharmaceuticals, Inc. (CRVS)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Corvus Pharmaceuticals, Inc. (CRVS)
Go deeper and ask any question about CRVS
Company Performance
Current Price
as of Sep 13, 2024$5.10
P/E Ratio
N/A
Market Cap
$319.01M
Description
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
Metrics
Overview
- HQBurlingame, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerCRVS
- Price$5.1-0.58%
Trading Information
- Market Cap$319.01M
- Float80.13%
- Average Daily Volume (1m)410,679
- Average Daily Volume (3m)319,930
- EPS-$0.45
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$4.26M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$5.91M
- EV$62.13M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account